ArticleThe American journal of pathology2011

Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.

Hui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.